You can find the annual or quarterly income statement of Mereo BioPharma Group PLC here for insights into the performance and operational efficiency of Mereo BioPharma Group PLC.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q2

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023H1

FY2022H2

FY2022H1

FY2021H2

FY2021H1

FY2020H2

FY2020H1

FY2019H2

FY2019H1

FY2018H2

FY2018H1

FY2017H2

FY2017H1

FY2016H2

FY2016H1

Total revenue

-100.00%0.00

----

--0.00

--500.00K

----

--0.00

--8.79M

--0.00

-100.00%0.00

--0.00

--50.59M

----

Revenue

-100.00%0.00

----

--0.00

--500.00K

----

--0.00

--8.79M

--0.00

-100.00%0.00

--0.00

--50.59M

----

Cost of revenue

-100.00%0.00

----

--0.00

--132.00K

----

--0.00

762.50%3.03M

-119.76%-685.80K

-101.82%-456.75K

---312.07K

--25.16M

----

Operating expenses

-36.09%7.03M

-21.75%8.77M

-45.07%8.39M

6.85%10.02M

-14.16%11.00M

13.15%11.20M

--15.28M

--9.37M

--12.81M

--9.90M

-13.32%24.53M

-9.56%25.55M

-44.37%28.30M

3.64%28.25M

141.93%50.87M

2.41%27.26M

-13.67%21.03M

24.58%26.62M

-1.37%24.36M

-14.02%21.37M

-25.77%24.70M

1.01%24.85M

37.28%33.27M

--24.60M

--24.23M

R&D expenses

-66.35%1.81M

20.79%4.75M

-52.47%4.19M

34.70%4.27M

8.63%5.37M

-1.60%3.93M

--8.82M

--3.17M

--4.95M

--3.99M

-43.68%9.73M

-26.79%13.67M

26.40%17.29M

81.74%18.67M

28.03%13.68M

-30.22%10.27M

-30.69%10.68M

-3.91%14.72M

3.19%15.41M

-11.93%15.32M

-44.54%14.93M

1.39%17.40M

68.91%26.93M

--17.16M

--15.94M

Depreciation, depletion, and amortization

----

-36.67%171.00K

67.88%460.00K

-86.17%39.00K

-36.96%162.00K

-1.82%270.00K

--274.00K

--282.00K

--257.00K

--275.00K

-11.98%497.96K

-34.36%341.72K

56.84%565.75K

-31.38%520.57K

-71.87%360.71K

-41.23%758.62K

36.95%1.28M

5567.58%1.29M

3273.35%936.48K

-7.12%22.78K

26.33%27.76K

14.72%24.52K

-7.93%21.97K

--21.38K

--23.87K

Other operating expenses

----

--0.00

---300.00K

----

Operating profit

33.04%-7.03M

21.75%-8.77M

45.07%-8.39M

-6.85%-10.02M

18.07%-10.50M

-13.15%-11.20M

---15.28M

---9.37M

---12.81M

---9.90M

44.37%-15.74M

9.56%-25.55M

-9899.49%-28.30M

-3.64%-28.25M

98.65%-283.02K

-2.41%-27.26M

13.67%-21.03M

-24.58%-26.62M

1.37%-24.36M

14.02%-21.37M

25.77%-24.70M

-1.01%-24.85M

-37.28%-33.27M

---24.60M

---24.23M

Net non-operating interest income (expenses)

Non-operating interest income

-52.80%278.00K

-50.38%327.00K

-52.21%421.00K

-48.73%504.00K

5.37%589.00K

6.81%659.00K

--881.00K

--983.00K

--559.00K

--617.00K

201.99%677.92K

--614.17K

16080.75%224.48K

-100.00%0.00

-97.18%1.39K

410.22%1.54M

-72.27%49.13K

50.16%302.23K

-14.91%177.15K

--201.27K

-17.01%208.20K

----

1890.24%250.89K

--237.87K

--12.61K

Non-operating interest expense

-33.33%16.00K

-88.89%20.00K

-93.87%23.00K

-92.07%28.00K

-92.75%24.00K

-41.94%180.00K

--375.00K

--353.00K

--331.00K

--310.00K

-38.77%1.33M

-45.47%1.40M

-17.17%2.18M

-57.27%2.56M

-25.74%2.63M

133.02%5.99M

33.36%3.54M

-10.49%2.57M

21.80%2.66M

371.29%2.87M

--2.18M

--609.54K

----

Gains from sale of securities

93.20%-362.00K

158.88%1.63M

97.24%-126.00K

129.15%1.87M

-17280.65%-5.33M

-551.06%-2.77M

---4.57M

---6.42M

--31.00K

--613.00K

-225.93%-2.29M

-300.53%-434.50K

196.56%1.82M

112.31%216.68K

-137.55%-1.89M

-377.78%-1.76M

-208.43%-793.67K

624.77%633.63K

-479.68%-257.32K

73.37%-120.75K

105.18%67.77K

-115.70%-453.47K

---1.31M

--2.89M

----

Special income (expenses)

105.94%6.00K

-95.91%17.00K

87.26%294.00K

432.20%196.00K

-46.38%-101.00K

192.86%416.00K

--157.00K

---59.00K

---69.00K

---448.00K

-71.35%449.89K

-77.87%7.74M

-92.12%1.57M

124.41%34.99M

29943.75%19.93M

-30035740.79%-143.36M

-102.84%-66.77K

-100.05%-477.31

--2.35M

--926.57K

----

- Gains from disposal of fixed assets

----

-100.00%0.00

--0.00

-72.57%153.99K

100.00%0.00

--561.46K

---14.24M

----

--0.00

----

Other non-operating income (expenses)

-84.03%119.00K

-48.65%95.00K

-17.88%473.00K

97.35%446.00K

101.90%745.00K

-61.22%185.00K

--576.00K

--226.00K

--369.00K

--477.00K

235.45%3.53M

--0.00

--1.05M

----

--123.59M

-20322.42%-119.24M

----

--589.64K

----

Income before tax

52.07%-7.00M

47.86%-6.72M

-4.33%-7.35M

53.18%-7.02M

-19.27%-14.62M

-43.97%-12.89M

---7.05M

---15.00M

---12.26M

---8.95M

43.00%-14.71M

-518.34%-19.02M

-270.63%-25.81M

108.63%4.55M

109.52%15.13M

-86.46%-52.68M

-557.61%-158.86M

-21.61%-28.26M

9.19%-24.16M

10.34%-23.23M

22.50%-26.60M

-20.67%-25.91M

-41.72%-34.33M

---21.48M

---24.22M

Income tax

--0.00

-17.22%-1.12M

-137.09%-1.36M

41.94%-953.72K

310.29%3.68M

12.02%-1.64M

63.59%-1.75M

41.28%-1.87M

-27.51%-4.81M

2.19%-3.18M

20.71%-3.77M

43.15%-3.25M

-17.82%-4.75M

-83.75%-5.72M

---4.03M

---3.11M

Income after tax

52.07%-7.00M

47.86%-6.72M

-4.33%-7.35M

53.18%-7.02M

-19.27%-14.62M

-43.97%-12.89M

---7.05M

---15.00M

---12.26M

---8.95M

45.31%-13.60M

-2134.31%-17.66M

-248.23%-24.86M

101.70%868.07K

110.68%16.77M

-117.20%-50.93M

-648.39%-156.99M

-20.47%-23.45M

10.16%-20.98M

8.02%-19.47M

18.38%-23.35M

-21.33%-21.16M

-35.52%-28.61M

---17.44M

---21.11M

Net income from continuous operations

52.07%-7.00M

47.86%-6.72M

-4.33%-7.35M

53.18%-7.02M

-19.27%-14.62M

-43.97%-12.89M

---7.05M

---15.00M

---12.26M

---8.95M

45.31%-13.60M

-2134.31%-17.66M

-248.23%-24.86M

101.70%868.07K

110.68%16.77M

-117.20%-50.93M

-648.39%-156.99M

-20.47%-23.45M

10.16%-20.98M

8.02%-19.47M

18.38%-23.35M

-21.33%-21.16M

-35.52%-28.61M

---17.44M

---21.11M

Net income attributable to controlling interests

52.07%-7.00M

47.86%-6.72M

-4.33%-7.35M

53.18%-7.02M

-19.27%-14.62M

-43.97%-12.89M

---7.05M

---15.00M

---12.26M

---8.95M

45.31%-13.60M

-2134.31%-17.66M

-248.23%-24.86M

101.70%868.07K

110.68%16.77M

-117.20%-50.93M

-648.39%-156.99M

-20.47%-23.45M

10.16%-20.98M

8.02%-19.47M

18.38%-23.35M

-21.33%-21.16M

-35.52%-28.61M

---17.44M

---21.11M

Net income attributable to common shareholders

52.07%-7.00M

47.86%-6.72M

-4.33%-7.35M

53.18%-7.02M

-19.27%-14.62M

-43.97%-12.89M

---7.05M

---15.00M

---12.26M

---8.95M

45.31%-13.60M

-2134.31%-17.66M

-248.23%-24.86M

101.70%868.07K

110.68%16.77M

-117.20%-50.93M

-648.39%-156.99M

-20.47%-23.45M

10.16%-20.98M

8.02%-19.47M

18.38%-23.35M

-21.33%-21.16M

-35.52%-28.61M

---17.44M

---21.11M

Basic earnings per share

52.30%-0.01

49.00%-0.01

-0.99%-0.01

54.93%-0.01

-6.16%-0.02

-28.56%-0.02

---0.01

---0.02

---0.01

49.07%-0.02

-1930.32%-0.03

-225.54%-0.04

101.03%0.00

102.56%0.03

32.65%-0.15

-365.01%-1.32

18.41%-0.22

13.38%-0.28

8.51%-0.27

22.84%-0.33

-10.80%-0.30

49.77%-0.43

---0.27

---0.85

Diluted earnings per share

52.30%-0.01

49.00%-0.01

-0.99%-0.01

54.93%-0.01

-6.16%-0.02

-28.56%-0.02

---0.01

---0.02

---0.01

49.07%-0.02

-1930.32%-0.03

-237.81%-0.04

101.03%0.00

102.34%0.03

32.65%-0.15

-365.01%-1.32

18.41%-0.22

13.38%-0.28

8.51%-0.27

22.84%-0.33

-10.80%-0.30

49.77%-0.43

---0.27

---0.85

Dividend per share

----

--0.00

----

--0.00

Currency unit

--USD

Audit opinions

----

FAQs

How do I read Mereo BioPharma Group PLC's income statement on TradingKey?



Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?



A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?



YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing MREO stock?



Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Mereo BioPharma Group PLC's revenue at year end?



Mereo BioPharma Group PLC reported 500.00K in revenue for fiscal year 2025, up from 500.00K in the previous year.

What was Mereo BioPharma Group PLC's net income for the year?



Mereo BioPharma Group PLC posted -41.88M in net income for fiscal year 2025.

How much net income did Mereo BioPharma Group PLC post in the last quarter?



Mereo BioPharma Group PLC reported -6.72M in net income for the latest quarter。

What was Mereo BioPharma Group PLC's annual operating profit?



Mereo BioPharma Group PLC's operating income was -40.11M for fiscal year 2025.

How is EPS related to the income statement?



EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.